http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011104705-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37 |
| filingDate | 2009-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011104705-A |
| titleOfInvention | VILLEBRAND VON FACTOR OR VIII FACTOR AND VILLEBRAND FACTOR FOR TREATMENT OF COAGULOPATHY INDUCED BY THROMBOCYTES INHIBITORS |
| abstract | 1. Von Willebrand factor (vWF) for the treatment and / or prophylaxis of a bleeding episode associated with thrombopathy induced by platelet-inhibiting substances. ! 2. vWF according to claim 1, where vWF is used or administered in combination with factor VIII as a combination of factor VIII / von Willebrand factor (FVIII / vWF). ! 3. vWF according to claim 1, where vWF or FVIII / vWF is administered to act as an antidote. ! 4. vWF according to claim 1, where vWF or FVIII / vWF is used or administered as a concentrate. ! 5. vWF according to claim 1, where vWF or FVIII / vWF is isolated from human blood plasma. ! 6. vWF according to claim 1, where vWF or FVIII / vWF is administered as a recombinant protein. ! 7. vWF according to claim 1, where vWF or FVIII / vWF is administered to a patient at a dose of 10 to 1000 units of vWF per kg body weight or 5-400 units of FVIII and 10-1000 units of vWF per kg body weight. ! 8. vWF according to claim 7, where vWF or FVIII / vWF is administered to a patient at a dose of 30 to 500 units of vWF per kg body weight or 20-200 units of FVIII and 30-500 units of vWF per kg body weight. ! 9. vWF according to claim 1, where the platelet inhibitory substance is a cyclooxygenase inhibitor, an ADP receptor inhibitor, or a combination thereof. ! 10. vWF according to claim 9, wherein the cyclooxygenase inhibitor is acetylsalicylic acid and wherein the ADP receptor inhibitor is a thienopyridine derivative, preferably clopidogrel or ticlopidine. ! 11. A method of preparing a medicament for the treatment and / or prophylaxis of a bleeding disorder associated with thrombopathy induced by platelet-inhibiting substances using a pharmaceutically effective amount of von Willebrand factor (vWF). ! 12. The method according to claim 11, where vWF is used or administered in combination with factor VIII as a combination of factor VIII / von Willebrand factor (FVIII / vWF). ! 13. The method according to claim 11, where vWF or FVIII / vWF is administered for action |
| priorityDate | 2008-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.